DOXORUBICIN ACCORD doxorubicin hydrochloride 10mg/5ml concentrated solution for injection Australia - English - Department of Health (Therapeutic Goods Administration)

doxorubicin accord doxorubicin hydrochloride 10mg/5ml concentrated solution for injection

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 10 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

DOXORUBICIN ACCORD doxorubicin hydrochloride 200 mg/100 mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

doxorubicin accord doxorubicin hydrochloride 200 mg/100 ml concentrated solution for injection vial

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Naloxone (Min-I-Jet) New Zealand - English - Medsafe (Medicines Safety Authority)

naloxone (min-i-jet)

pharmacy retailing (nz) ltd t/a healthcare logistics - naloxone hydrochloride dihydrate 0.4 mg/ml;   - solution for injection - 0.4 mg/ml - active: naloxone hydrochloride dihydrate 0.4 mg/ml   excipient: hydrochloric acid sodium chloride water for injection - naloxone is indicated for the complete or partial reversal of narcotic depression, including respiratory depression, induced by natural and synthetic opioids such as codeine, diamorphine, methadone, morphine and propoxyphene. it is also indicated for the diagnosis of suspected acute opioid overdosage.

DOXORUBICIN EBEWE 2 MGML Israel - English - Ministry of Health

doxorubicin ebewe 2 mgml

novartis israel ltd - doxorubicin hydrochloride - solution for injection/ concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - doxorubicin - doxorubicin - soft tissue and bone sarcomas, hodgkin's and non-hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms` tumor, carcinomas of the thyroid, breast, ovary, bladder, small cell bronchogenic carcinoma and neuroblastoma.

Doxorubicin Hydrochloride (Hospira) New Zealand - English - Medsafe (Medicines Safety Authority)

doxorubicin hydrochloride (hospira)

pfizer new zealand limited - doxorubicin hydrochloride 10mg - powder for injection - 10 mg - active: doxorubicin hydrochloride 10mg excipient: lactose monohydrate - doxorubicin has produced significant therapeutic responses in a number of solid tumours and haematologic malignancies, and is commonly used in the treatment of the following tumours: · carcinoma of the breast · carcinoma of the lung · carcinoma of the ovary · transitional bladder cell cancer · neuroblastoma · wilms' tumour · soft tissue sarcomas · osteosarcoma · acute lymphocytic - lymphoblastic leukaemia · acute myelogenous leukaemia · non-hodgkin's lymphoma · hodgkin's disease doxorubicin has also shown antitumour activity in the following adult and paediatric malignancies: · carcinoma of the thyroid · carcinoma of the endometrium · carcinoma of the head and neck · carcinoma of the stomach · primary hepatocellular carcinoma · non-seminomatous carcinoma of the testis · carcinoma of the prostate · ewing's sarcoma · rhabdomyosarcoma · multiple myeloma · chronic leukaemias

Doxorubicin Hydrochloride (Hospira) New Zealand - English - Medsafe (Medicines Safety Authority)

doxorubicin hydrochloride (hospira)

pfizer new zealand limited - doxorubicin hydrochloride 50mg - powder for injection - 50 mg - active: doxorubicin hydrochloride 50mg excipient: lactose monohydrate - doxorubicin has produced significant therapeutic responses in a number of solid tumours and haematologic malignancies, and is commonly used in the treatment of the following tumours: · carcinoma of the breast · carcinoma of the lung · carcinoma of the ovary · transitional bladder cell cancer · neuroblastoma · wilms' tumour · soft tissue sarcomas · osteosarcoma · acute lymphocytic - lymphoblastic leukaemia · acute myelogenous leukaemia · non-hodgkin's lymphoma · hodgkin's disease doxorubicin has also shown antitumour activity in the following adult and paediatric malignancies: · carcinoma of the thyroid · carcinoma of the endometrium · carcinoma of the head and neck · carcinoma of the stomach · primary hepatocellular carcinoma · non-seminomatous carcinoma of the testis · carcinoma of the prostate · ewing's sarcoma · rhabdomyosarcoma · multiple myeloma · chronic leukaemias

DOXORUBICIN Ireland - English - HPRA (Health Products Regulatory Authority)

doxorubicin

accord healthcare limited - doxorubicin hydrochloride - concentrate for soln for inf - 2 mg/ml - doxorubicin

Doxorubicin Actavis 2mg/ml concentrate for solution for infusion (10mg/5ml) Malta - English - Medicines Authority

doxorubicin actavis 2mg/ml concentrate for solution for infusion (10mg/5ml)

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - antineoplastic agents

Naloxone Hydrochloride 400 micrograms/ml Solution for Injection/Infusion Malta - English - Medicines Authority

naloxone hydrochloride 400 micrograms/ml solution for injection/infusion

mercury pharma international limited 4045 kingswood road, city west business park, co, dublin, ireland - naloxone hydrochloride - solution for injection - naloxone hydrochloride 400 µg/ml - all other therapeutic products

Naloxone Hydrochloride Hameln New Zealand - English - Medsafe (Medicines Safety Authority)

naloxone hydrochloride hameln

max health limited - naloxone hydrochloride dihydrate 0.44 mg/ml equivalent to 0.40 mg naloxone hydrochloride - solution for injection - 400 mcg/ml - active: naloxone hydrochloride dihydrate 0.44 mg/ml equivalent to 0.40 mg naloxone hydrochloride excipient: hydrochloric acid sodium chloride water for injection - naloxone hydrochloride injection is indicated for the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic antagonist analgesics: nalbuphine, pentazocine and butorphanol. naloxone hydrochloride is also indicated for the diagnosis of suspected acute opioid overdosage.